Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 257

1.

Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids.

Tokunaga A, Sugiyama D, Maeda Y, Warner AB, Panageas KS, Ito S, Togashi Y, Sakai C, Wolchok JD, Nishikawa H.

J Exp Med. 2019 Sep 19. pii: jem.20190738. doi: 10.1084/jem.20190738. [Epub ahead of print]

PMID:
31537643
2.

Clinical and immune profiling for cancer of unknown primary site.

Haratani K, Hayashi H, Takahama T, Nakamura Y, Tomida S, Yoshida T, Chiba Y, Sawada T, Sakai K, Fujita Y, Togashi Y, Tanizaki J, Kawakami H, Ito A, Nishio K, Nakagawa K.

J Immunother Cancer. 2019 Sep 13;7(1):251. doi: 10.1186/s40425-019-0720-z.

3.

Influence of Timing of Insulin Initiation on Long-term Glycemic Control in Japanese Patients with Type 2 Diabetes: A Retrospective Cohort Study.

Miyazaki T, Shirakawa J, Nagakura J, Shibuya M, Kyohara M, Okuyama T, Togashi Y, Nakamura A, Kondo Y, Satoh S, Nakajima S, Taguri M, Terauchi Y.

Intern Med. 2019 Jul 22. doi: 10.2169/internalmedicine.3060-19. [Epub ahead of print]

4.

Vocal cord inflammatory myofibroblastic tumor with mucoid deposits harboring TIMP3-ALK fusion: A potential diagnostic pitfall.

Yorita K, Togashi Y, Nakagawa H, Miyazaki K, Sakata S, Baba S, Takeuchi K, Hayashi Y, Murakami I, Kuroda N, Oda Y, Kohashi K, Yamada Y, Kiyozawa D, Michal M, Michal M.

Pathol Int. 2019 Jun;69(6):366-371. doi: 10.1111/pin.12796. Epub 2019 Jun 18.

PMID:
31215130
5.

Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity.

Tanegashima T, Togashi Y, Azuma K, Kawahara A, Ideguchi K, Sugiyama D, Kinoshita F, Akiba J, Kashiwagi E, Takeuchi A, Irie T, Tatsugami K, Hoshino T, Eto M, Nishikawa H.

Clin Cancer Res. 2019 Aug 1;25(15):4808-4819. doi: 10.1158/1078-0432.CCR-18-3991. Epub 2019 May 10.

PMID:
31076547
6.

PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.

Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, Sato E, Fukuoka S, Tada Y, Tanaka A, Morikawa H, Kawazoe A, Kinoshita T, Shitara K, Sakaguchi S, Nishikawa H.

Proc Natl Acad Sci U S A. 2019 May 14;116(20):9999-10008. doi: 10.1073/pnas.1822001116. Epub 2019 Apr 26.

7.

Time Course of Axon and Myelin Degeneration in Peripheral Nerves in Experimental Autoimmune Neuritis Rats.

Tomikawa E, Mutsuga M, Hara K, Kaneko C, Togashi Y, Miyamoto Y.

Toxicol Pathol. 2019 Jun;47(4):542-552. doi: 10.1177/0192623319838993. Epub 2019 Apr 15.

PMID:
30987532
8.

Chylothorax after spinal fusion surgery: A case report and literature review.

Toriyama K, Kokuho N, Yajima C, Kawagoe J, Togashi Y, Tsuji T, Nakayama H, Abe S.

Respir Med Case Rep. 2019 Feb 5;26:260-264. doi: 10.1016/j.rmcr.2019.02.004. eCollection 2019.

9.

Regulatory T cells in cancer immunosuppression - implications for anticancer therapy.

Togashi Y, Shitara K, Nishikawa H.

Nat Rev Clin Oncol. 2019 Jun;16(6):356-371. doi: 10.1038/s41571-019-0175-7. Review.

PMID:
30705439
10.

Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Anti-PD-1 Therapy.

Inozume T, Yaguchi T, Ariyasu R, Togashi Y, Ohnuma T, Honobe A, Nishikawa H, Kawakami Y, Kawamura T.

J Invest Dermatol. 2019 Jul;139(7):1490-1496. doi: 10.1016/j.jid.2019.01.007. Epub 2019 Jan 23.

PMID:
30684558
11.

Modeling of Nanomachine/Micromachine Crowds: Interplay between the Internal State and Surroundings.

Togashi Y.

J Phys Chem B. 2019 Feb 21;123(7):1481-1490. doi: 10.1021/acs.jpcb.8b10633. Epub 2019 Feb 12.

PMID:
30681855
12.

Coarse-Grained Protein Dynamics Studies Using Elastic Network Models.

Togashi Y, Flechsig H.

Int J Mol Sci. 2018 Dec 5;19(12). pii: E3899. doi: 10.3390/ijms19123899. Review.

13.

Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer.

Watanabe S, Hayashi H, Haratani K, Shimizu S, Tanizaki J, Sakai K, Kawakami H, Yonesaka K, Tsurutani J, Togashi Y, Nishio K, Ito A, Nakagawa K.

Cancer Sci. 2019 Jan;110(1):52-60. doi: 10.1111/cas.13860. Epub 2018 Nov 27.

14.

Designed Elastic Networks: Models of Complex Protein Machinery.

Flechsig H, Togashi Y.

Int J Mol Sci. 2018 Oct 13;19(10). pii: E3152. doi: 10.3390/ijms19103152. Review.

15.

Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment.

Tada Y, Togashi Y, Kotani D, Kuwata T, Sato E, Kawazoe A, Doi T, Wada H, Nishikawa H, Shitara K.

J Immunother Cancer. 2018 Oct 11;6(1):106. doi: 10.1186/s40425-018-0403-1.

16.

HERC2 Facilitates BLM and WRN Helicase Complex Interaction with RPA to Suppress G-Quadruplex DNA.

Wu W, Rokutanda N, Takeuchi J, Lai Y, Maruyama R, Togashi Y, Nishikawa H, Arai N, Miyoshi Y, Suzuki N, Saeki Y, Tanaka K, Ohta T.

Cancer Res. 2018 Nov 15;78(22):6371-6385. doi: 10.1158/0008-5472.CAN-18-1877. Epub 2018 Oct 2.

PMID:
30279242
17.

Single-molecule diffusion-based estimation of ligand effects on G protein-coupled receptors.

Yanagawa M, Hiroshima M, Togashi Y, Abe M, Yamashita T, Shichida Y, Murata M, Ueda M, Sako Y.

Sci Signal. 2018 Sep 18;11(548). pii: eaao1917. doi: 10.1126/scisignal.aao1917.

PMID:
30228224
18.

Allergic contact dermatitis caused by 2-hydroxyethyl acrylate in a moisturizing face pack in a handmade acrylic accessory enthusiast.

Mukaijo J, Inomata N, Higashihira M, Koh N, Togashi Y, Asai C, Watanabe Y, Kurihara S, Aihara M.

Contact Dermatitis. 2018 Dec;79(6):383-385. doi: 10.1111/cod.13088. Epub 2018 Aug 6. No abstract available.

PMID:
30079447
19.

Pediatric case with rice bran allergy induced by epicutaneous sensitization in a family rice shop.

Togashi Y, Inomata N, Suzuki A, Hakuta A, Aihara M.

Allergol Int. 2019 Jan;68(1):117-118. doi: 10.1016/j.alit.2018.05.010. Epub 2018 Jun 18. No abstract available.

20.

Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer.

Kawazoe A, Shitara K, Kuboki Y, Bando H, Kojima T, Yoshino T, Ohtsu A, Ochiai A, Togashi Y, Nishikawa H, Doi T, Kuwata T.

Gastric Cancer. 2019 Jan;22(1):69-76. doi: 10.1007/s10120-018-0843-9. Epub 2018 Jun 1.

PMID:
29859006
21.

Epithelioid cell histiocytoma with SQSTM1-ALK fusion: a case report.

Nakayama R, Togashi Y, Baba S, Kaku Y, Teramoto Y, Sakurai T, Haga H, Takeuchi K.

Diagn Pathol. 2018 May 10;13(1):28. doi: 10.1186/s13000-018-0704-1.

22.

TP53 and OSBPL10 alterations in diffuse large B-cell lymphoma: prognostic markers identified via exome analysis of cases with extreme prognosis.

Dobashi A, Togashi Y, Tanaka N, Yokoyama M, Tsuyama N, Baba S, Mori S, Hatake K, Yamaguchi T, Noda T, Takeuchi K.

Oncotarget. 2018 Apr 13;9(28):19555-19568. doi: 10.18632/oncotarget.24656. eCollection 2018 Apr 13.

23.

A case report of atypical Spitz tumor harboring a novel MLPH-ALK gene fusion with discordant ALK immunohistochemistry results.

Fujimoto M, Togashi Y, Matsuzaki I, Baba S, Takeuchi K, Inaba Y, Jinnin M, Murata SI.

Hum Pathol. 2018 Oct;80:99-103. doi: 10.1016/j.humpath.2018.02.021. Epub 2018 Apr 4.

PMID:
29514107
24.

Signaling between pancreatic β cells and macrophages via S100 calcium-binding protein A8 exacerbates β-cell apoptosis and islet inflammation.

Inoue H, Shirakawa J, Togashi Y, Tajima K, Okuyama T, Kyohara M, Tanaka Y, Orime K, Saisho Y, Yamada T, Shibue K, Kulkarni RN, Terauchi Y.

J Biol Chem. 2018 Apr 20;293(16):5934-5946. doi: 10.1074/jbc.M117.809228. Epub 2018 Mar 1.

25.

MYB and MYBL1 in adenoid cystic carcinoma: diversity in the mode of genomic rearrangement and transcripts.

Togashi Y, Dobashi A, Sakata S, Sato Y, Baba S, Seto A, Mitani H, Kawabata K, Takeuchi K.

Mod Pathol. 2018 Jun;31(6):934-946. doi: 10.1038/s41379-018-0008-8. Epub 2018 Feb 6.

26.

Suppression from beyond the grave.

Togashi Y, Nishikawa H.

Nat Immunol. 2017 Nov 16;18(12):1285-1286. doi: 10.1038/ni.3870. No abstract available.

PMID:
29144496
27.

Serum Quantitative Proteomic Analysis Reveals Soluble EGFR To Be a Marker of Insulin Resistance in Male Mice and Humans.

Kyohara M, Shirakawa J, Okuyama T, Kimura A, Togashi Y, Tajima K, Hirano H, Terauchi Y.

Endocrinology. 2017 Dec 1;158(12):4152-4164. doi: 10.1210/en.2017-00339.

PMID:
29028997
28.

The case of double primary lung adenocarcinomas with an EGFR mutation and ALK translocation successfully treated with alectinib at the post-surgical recurrence.

Tsunezuka Y, Tanaka N, Fujimori H, Togashi Y, Baba S, Takeuchi K, Katayanagi K, Kurumaya H, Kitade H, Atagi S, Yano S.

J Med Invest. 2017;64(3.4):305-307. doi: 10.2152/jmi.64.305.

29.

Regulatory T Cells: Molecular and Cellular Basis for Immunoregulation.

Togashi Y, Nishikawa H.

Curr Top Microbiol Immunol. 2017;410:3-27. doi: 10.1007/82_2017_58. Review.

PMID:
28879523
30.

Metabolic recovery of lipodystrophy, liver steatosis, and pancreatic β cell proliferation after the withdrawal of OSI-906.

Tajima K, Shirakawa J, Togashi Y, Yamazaki S, Okuyama T, Kyohara M, Konishi H, Terauchi Y.

Sci Rep. 2017 Jun 23;7(1):4119. doi: 10.1038/s41598-017-04304-5.

31.

Identification of the matricellular protein Fibulin-5 as a target molecule of glucokinase-mediated calcineurin/NFAT signaling in pancreatic islets.

Okuyama T, Shirakawa J, Yanagisawa H, Kyohara M, Yamazaki S, Tajima K, Togashi Y, Terauchi Y.

Sci Rep. 2017 May 24;7(1):2364. doi: 10.1038/s41598-017-02535-0.

32.

Effects of metformin on compensatory pancreatic β-cell hyperplasia in mice fed a high-fat diet.

Tajima K, Shirakawa J, Okuyama T, Kyohara M, Yamazaki S, Togashi Y, Terauchi Y.

Am J Physiol Endocrinol Metab. 2017 Sep 1;313(3):E367-E380. doi: 10.1152/ajpendo.00447.2016. Epub 2017 May 16.

33.

Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib.

Banno E, Togashi Y, de Velasco MA, Mizukami T, Nakamura Y, Terashima M, Sakai K, Fujita Y, Kamata K, Kitano M, Kudo M, Nishio K.

Int J Oncol. 2017 Jun;50(6):2049-2058. doi: 10.3892/ijo.2017.3961. Epub 2017 Apr 18.

PMID:
28440469
34.

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A.

Chiba M, Togashi Y, Bannno E, Kobayashi Y, Nakamura Y, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K.

BMC Cancer. 2017 Apr 19;17(1):281. doi: 10.1186/s12885-017-3263-z. No abstract available.

35.

Aminoglutethimide-induced lysosomal changes in adrenal gland in mice.

Mutsuga M, Asaoka Y, Imura N, Miyoshi T, Togashi Y.

Exp Toxicol Pathol. 2017 Sep 5;69(7):424-429. doi: 10.1016/j.etp.2017.04.004. Epub 2017 Apr 11.

PMID:
28410883
36.

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.

Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K, Hayashi K, Tomida S, Chiba Y, Yonesaka K, Nonagase Y, Takahama T, Tanizaki J, Tanaka K, Yoshida T, Tanimura K, Takeda M, Yoshioka H, Ishida T, Mitsudomi T, Nishio K, Nakagawa K.

Ann Oncol. 2017 Jul 1;28(7):1532-1539. doi: 10.1093/annonc/mdx183.

PMID:
28407039
37.

Bridging the dynamics and organization of chromatin domains by mathematical modeling.

Shinkai S, Nozaki T, Maeshima K, Togashi Y.

Nucleus. 2017 Jul 4;8(4):353-359. doi: 10.1080/19491034.2017.1313937. Epub 2017 Apr 13.

38.

The 1-Particle-per-k-Nucleotides (1PkN) Elastic Network Model of DNA Dynamics with Sequence-Dependent Geometry.

Kameda T, Isami S, Togashi Y, Nishimori H, Sakamoto N, Awazu A.

Front Physiol. 2017 Mar 14;8:103. doi: 10.3389/fphys.2017.00103. eCollection 2017.

39.

Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.

Kobayashi Y, Azuma K, Nagai H, Kim YH, Togashi Y, Sesumi Y, Chiba M, Shimoji M, Sato K, Tomizawa K, Takemoto T, Nishio K, Mitsudomi T.

Mol Cancer Ther. 2017 Feb;16(2):357-364. doi: 10.1158/1535-7163.MCT-16-0407. Epub 2016 Dec 2.

40.

Non-RVD mutations that enhance the dynamics of the TAL repeat array along the superhelical axis improve TALEN genome editing efficacy.

Tochio N, Umehara K, Uewaki JI, Flechsig H, Kondo M, Dewa T, Sakuma T, Yamamoto T, Saitoh T, Togashi Y, Tate SI.

Sci Rep. 2016 Nov 24;6:37887. doi: 10.1038/srep37887.

41.

Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.

Tanizaki J, Banno E, Togashi Y, Hayashi H, Sakai K, Takeda M, Kaneda H, Nishio K, Nakagawa K.

Lung Cancer. 2016 Nov;101:11-15. doi: 10.1016/j.lungcan.2016.09.001. Epub 2016 Sep 4.

PMID:
27794398
42.

HP1 regulates the localization of FANCJ at sites of DNA double-strand breaks.

Wu W, Togashi Y, Johmura Y, Miyoshi Y, Nobuoka S, Nakanishi M, Ohta T.

Cancer Sci. 2016 Oct;107(10):1406-1415. doi: 10.1111/cas.13008. Epub 2016 Sep 1.

43.

Dynamic Nucleosome Movement Provides Structural Information of Topological Chromatin Domains in Living Human Cells.

Shinkai S, Nozaki T, Maeshima K, Togashi Y.

PLoS Comput Biol. 2016 Oct 20;12(10):e1005136. doi: 10.1371/journal.pcbi.1005136. eCollection 2016 Oct.

44.

MEK inhibitors against MET-amplified non-small cell lung cancer.

Chiba M, Togashi Y, Tomida S, Mizuuchi H, Nakamura Y, Banno E, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K.

Int J Oncol. 2016 Dec;49(6):2236-2244. doi: 10.3892/ijo.2016.3736. Epub 2016 Oct 17.

45.

FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.

Hibi M, Kaneda H, Tanizaki J, Sakai K, Togashi Y, Terashima M, De Velasco MA, Fujita Y, Banno E, Nakamura Y, Takeda M, Ito A, Mitsudomi T, Nakagawa K, Okamoto I, Nishio K.

Cancer Sci. 2016 Nov;107(11):1667-1676. doi: 10.1111/cas.13071.

46.

Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?

Banno E, Togashi Y, Nakamura Y, Chiba M, Kobayashi Y, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K.

Cancer Sci. 2016 Aug;107(8):1134-40. doi: 10.1111/cas.12980. Epub 2016 Jul 14.

47.

Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.

Nakamura Y, Togashi Y, Nakahara H, Tomida S, Banno E, Terashima M, Hayashi H, de Velasco MA, Sakai K, Fujita Y, Okegawa T, Nutahara K, Hamada S, Nishio K.

Mol Cancer Ther. 2016 Aug;15(8):1988-97. doi: 10.1158/1535-7163.MCT-15-0737. Epub 2016 May 20.

48.

Evaluation of the appropriateness of using glucometers for measuring the blood glucose levels in mice.

Togashi Y, Shirakawa J, Okuyama T, Yamazaki S, Kyohara M, Miyazawa A, Suzuki T, Hamada M, Terauchi Y.

Sci Rep. 2016 May 6;6:25465. doi: 10.1038/srep25465.

49.
50.

Mouse models for ROS1-fusion-positive lung cancers and their application to the analysis of multikinase inhibitor efficiency.

Inoue M, Toki H, Matsui J, Togashi Y, Dobashi A, Fukumura R, Gondo Y, Minowa O, Tanaka N, Mori S, Takeuchi K, Noda T.

Carcinogenesis. 2016 May;37(5):452-60. doi: 10.1093/carcin/bgw028. Epub 2016 Mar 10.

PMID:
26964870

Supplemental Content

Loading ...
Support Center